COPD Foundation Launches New Program to Spur Research
The COPD Foundation has announced the launch of COPD360, an exciting new initiative to help patients. COPD360 is an innovative approach to accelerating research and developing new treatment options for chronic obstructive pulmonary disease (COPD).
“AstraZeneca is proud to be a founding sponsor of this pioneering effort,” said Greg Keenan, Vice President, Medical Affairs and U.S. Chief Medical Officer, AstraZeneca. “This is an innovative undertaking that we truly believe will enable faster recruitment for clinical trials and spur COPD research at an unprecedented level.”
COPD360 will enroll 125,000 patients, who have agreed to share their health data, in the integrated database, giving researchers a chance to explore patient-reported outcomes and new observational data. By having access to this information, researchers will be able to explore new areas of study and—hopefully—identify a cure for COPD.
“I would like to thank AstraZeneca for becoming a founding corporate sponsor of COPD360. This substantial commitment will make an immediate impact on our ability to enroll patients and to build a community of active research participants,” said John W. Walsh, COPD Foundation President and Co-Founder.
COPD is the third leading cause of death in the U.S. and affects more than 30 million Americans. Knowledge of this disease has expanded more recently and it is considered a complex disease with multiple comorbidities that can lead to frequent infections, hospital admissions and mortality. It is unknown why many individuals who are exposed to known risk factors, such as smoking, do not develop COPD. With a rising economic burden estimated at approximately $50 billion annually, there is a disproportionately low level of research funding allocated to this preventable progressive disease.
As the founding sponsor of COPD360, AstraZeneca provided $2.5 million to the COPD Foundation. We are the first company to provide large-scale funding for this type of national COPD database and are eager to see the impact it may have for patients with COPD over the next several years.
As respiratory leaders, this program aligns with AstraZeneca’s commitment to patients and finding novel approaches to improving care for individuals living with COPD.
For more information about COPD360 or to enroll in the program, please contact the COPD Foundation at 1-866-316-COPD (2673)